Twenty-four, adult, female Beagles were arranged by body weight from greatest to least and allocated to 2 groups of 12 dogs, using random numbers. Dogs were housed collectively in 2 adjacent metal buildings, each divided into 4 rooms measuring 2.1 X3.7 m. Each room was paneled and carpeted and had an access door to the outside with a connecting run that measured 2.1 X 9.1 m. Each run had a surface consisting of 5 cm of pea gravel overlayng 5 cm of sand, and was partially covered by an awning that provided shade at its proximal end. For placement in room/run units, dogs in each of the treated and control groups were allotted to 4 subgroups of 3 dogs each. Each subgroup of dogs was placed in a separate room/run unit. Units containing treatment or control subgroups were alternated to avoid placing identically treated subgroups adjacent to each other. Dogs of subgroups A, C, E, and G were treated with lufenuron monthly at a minimal target dosage of 10 mg/kg of body weight; those of subgroups B, D, F, and H were treated with excipient tablets. Dogs were treated on study days 7, 37, 68, and 98. Each dog was infested with 100 newly emerged, unfed, insectary-reared adult Ctenocephalides felis on each of study days 0 and 2. Thereafter, infestations on all dogs were dependent on continued development of fleas either in the indoor or outdoor environment. Numbers of fleas on each of the treated and control dogs were determined, using a nondestructive counting technique on days 6, 14, 21, 28, 35, 56, 70, 84, 98, 112, and 119. On study day 21 and on each collection day thereafter, numbers of adult fleas recovered from treated dogs were significantly (P < 0.05) fewer than those recovered from control dogs. Proportion reduction of fleas on treated vs control dogs exceeded 90% by study day 35 and 95% by study day 56. Efficacies exceeded 95% on all remaining study days except days 98 (94.4% and 119 (90%). Results of this study indicate that control of flea populations can be achieved in treated dogs approximately 4 to 5 weeks after initial treatment with lufenuron, and that continued monthly treatments will maintain effective control of flea infestations. Adverse reactions or side effects to treatment with lufenuron were not observed in dogs after treatment at any time throughout the study.

Thirty-two mixed-breed male and female cats were blocked by sex, arranged by body weight from greatest to least, and allocated to 4 groups of 8 (4 male, 4 female) cats, using random numbers. Cats in each of 3 groups were treated orally with a 7% suspension formulation of lufenuron at dosage of 15, 30, or 45 mg/kg of body weight. Cats in the fourth group were treated orally with an excipient suspension without lufenuron. Cats were infested with newly emerged, unfed cat fleas (Ctenocephalides felis felis) on days -7 and -3 before treatment and at approximately weekly intervals after treatment. Flea eggs were collected from beneath each cat on selected days before and after treatment and placed in an artificial rearing medium. Flea eggs and medium were kept for 35 days in an insectary to determine effects of lufenuron or excipient suspension on emergence of adults of the F1 generation. Lufenuron was 100% effective in inhibiting development of C felis at all dosages for 11 days after treatment. Thereafter, efficacy exceeded 92% in all dosages groups, On day 32, when the study was terminated, efficacy for each of the dosage groups was: 15 mg/kg, 95.2%; 30 mg/kg, 98.2%; and 45 mg/kg, 99.6%. Adverse reactions or side effects were not observed in cats, regardless of treatment dosage.

A single dose of lufenuron was administered to dogs to test its efficacy in controlling cat flea (Ctenocephalides felis) infestations for at least 30 days. Efficacy measurements revealed marked differences in the reproduction capability of fleas collected from dogs in the treatment vs the control group. Essentially, aU of the eggs collected from dogs treated with lufenuron were unable to develop into normal adult fleas. Conversely, in the control group, 68.6% of the flea eggs developed into normal adult progeny.

Antiparasitic efficacy of ivermectin against migrating Gasterophilus intestinalis was evaluated in 36 treated and 24 nontreated (n = 12) or vehicle-treated (n = 12) ponies experimentally and naturally infected with G intestinalis and naturally infected with G nasalis. Each pony was experimentally infected with 500 G intestinalis lst instars in 2 divided doses on days -14 and -7 before treatment. On day 0, ivermectin was administered at the rate of 200 microgram/kg of body weight by IV (n = 12) or IM injection (n = 12) or given as an oral paste (n = 12). Ponies were euthanatized and necropsied 21 days after treatment. In each nontreated or vehicle-treated pony, late lst-, lst- to 2nd-instar molt, and early 2nd-instars of G intestinalis were found in the mouth, and 2nd- and 3rd instars of G intestinalis and 3rd instars of G nasalis were found in the stomach. Bots were not found in any ivermectin-treated pony and, thus, ivermectin was 100% effective against oral and gastric stages. Adverse reactions were not observed in ponies given ivermectin by IM injection or orally, but 1 pony given the vehicle IV and 1 pony given ivermectin (in the vehicle) IV had an anaphylactic reaction, resulting in death of the ivermectin-treated pony. It was speculated that the adverse reaction was caused by histamines released in response to vehicle components given by IV injection.

Angora goats heavily infested with Chorioptes bovis were dipped one time in either 0.05% amitraz, 0.27% coumaphos, 0.05% fenvalerate, or 0.03% lindane, Control of the mites by the single dips was evaluated for 21 days. Amitraz caused 98% mortality of the mites initially. Both coumaphos and lindane caused greater than 85% mortality at 3 days, but mite numbers increased rapidly thereafter. Only fenvalerate killed all of the mites.